Skip to main content
Erschienen in: Current Osteoporosis Reports 4/2019

21.05.2019 | Skeletal Biology and Regulation (M Forwood and A Robling, Section Editors)

CaMKK2 Signaling in Metabolism and Skeletal Disease: a New Axis with Therapeutic Potential

verfasst von: Justin N. Williams, Uma Sankar

Erschienen in: Current Osteoporosis Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Age and metabolic disorders result in the accumulation of advanced glycation endproducts (AGEs), oxidative stress, and inflammation, which cumulatively cause a decline in skeletal health. Bone becomes increasingly vulnerable to fractures and its regenerative capacity diminishes under such conditions. With a rapidly aging population in the USA and the global increase in diabetes, efficacious, multi-dimensional therapies that can treat or prevent skeletal diseases associated with metabolic dysfunction and inflammatory disorders are acutely needed.

Recent Findings

Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) is a key regulator of nutrient intake, glucose metabolism, insulin production, and adipogenesis. Recent studies suggest a pivotal role for CaMKK2 in bone metabolism, fracture healing, and inflammation.

Summary

Aside from rekindling previous concepts of CaMKK2 as a potent regulator of whole-body energy homeostasis, this review emphasizes CaMKK2 as a potential therapeutic target to treat skeletal diseases that underlie metabolic conditions and inflammation.
Literatur
1.
Zurück zum Zitat Yelin EH, Cisternas M. Annual all-cause and incremental direct costs for all musculoskeletal diseases in current and 2014 dollars, United States 1996-2014. The burden of musculoskeletal diseases in the united States 2017. Yelin EH, Cisternas M. Annual all-cause and incremental direct costs for all musculoskeletal diseases in current and 2014 dollars, United States 1996-2014. The burden of musculoskeletal diseases in the united States 2017.
3.
Zurück zum Zitat Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review of Treatment Options. P T. 2018;43(2):92–104.PubMedPubMedCentral Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review of Treatment Options. P T. 2018;43(2):92–104.PubMedPubMedCentral
7.
Zurück zum Zitat Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, et al. FRAME study: the Foundation effect of building bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to Denosumab. J Bone Miner Res. 2018;33(7):1219–26. https://doi.org/10.1002/jbmr.3427.CrossRefPubMed Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, et al. FRAME study: the Foundation effect of building bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to Denosumab. J Bone Miner Res. 2018;33(7):1219–26. https://​doi.​org/​10.​1002/​jbmr.​3427.CrossRefPubMed
34.
Zurück zum Zitat Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889–901.CrossRefPubMed Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889–901.CrossRefPubMed
35.
39.
43.
47.
Zurück zum Zitat Broulik PD, Sefc L, Haluzik M. Effect of PPAR-gamma agonist rosiglitazone on bone mineral density and serum adipokines in C57BL/6 male mice. Folia Biol (Praha). 2011;57(4):133–8. Broulik PD, Sefc L, Haluzik M. Effect of PPAR-gamma agonist rosiglitazone on bone mineral density and serum adipokines in C57BL/6 male mice. Folia Biol (Praha). 2011;57(4):133–8.
58.
Zurück zum Zitat Confalone E, D'Alessio G, Furia A. IL-6 induction by TNFalpha and IL-1beta in an osteoblast-like cell line. Int J Biomed Sci. 2010;6(2):135–40.PubMedPubMedCentral Confalone E, D'Alessio G, Furia A. IL-6 induction by TNFalpha and IL-1beta in an osteoblast-like cell line. Int J Biomed Sci. 2010;6(2):135–40.PubMedPubMedCentral
69.
Zurück zum Zitat •• Tevlin R, Seo EY, Marecic O, McArdle A, Tong X, Zimdahl B, et al. Pharmacological rescue of diabetic skeletal stem cell niches. Sci Transl Med. 2017;9(372). https://doi.org/10.1126/scitranslmed.aag2809. Demonstrates a potential mechanism for type 2 diabetes to impair the skeletal stem cell response during bone fracture healing. •• Tevlin R, Seo EY, Marecic O, McArdle A, Tong X, Zimdahl B, et al. Pharmacological rescue of diabetic skeletal stem cell niches. Sci Transl Med. 2017;9(372). https://​doi.​org/​10.​1126/​scitranslmed.​aag2809. Demonstrates a potential mechanism for type 2 diabetes to impair the skeletal stem cell response during bone fracture healing.
70.
Metadaten
Titel
CaMKK2 Signaling in Metabolism and Skeletal Disease: a New Axis with Therapeutic Potential
verfasst von
Justin N. Williams
Uma Sankar
Publikationsdatum
21.05.2019
Verlag
Springer US
Erschienen in
Current Osteoporosis Reports / Ausgabe 4/2019
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-019-00518-w

Weitere Artikel der Ausgabe 4/2019

Current Osteoporosis Reports 4/2019 Zur Ausgabe

Skeletal Biology and Regulation (M Forwood and A Robling, Section Editors)

Investigating Osteocytic Perilacunar/Canalicular Remodeling

Skeletal Biology and Regulation (M Forwood and A Robling, Section Editors)

RNA-seq in Skeletal Biology

Skeletal Development (R Marcucio and J Feng, Section Editors)

Contextual Regulation of Skeletal Physiology by Notch Signaling

Regenerative Biology and Medicine in Osteoporosis (S Bryant and M Krebs, Section Editors)

Impact of Induced Pluripotent Stem Cells in Bone Repair and Regeneration

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.